NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,996,589 | +9.7% | 936,347 | +45.1% | 0.04% | +2.8% |
| Q2 2023 | $16,400,857 | -35.8% | 645,195 | -8.7% | 0.04% | -43.8% |
| Q1 2023 | $25,550,025 | +59.3% | 706,778 | +74.5% | 0.06% | +45.5% |
| Q4 2022 | $16,039,742 | -60.7% | 405,044 | -53.7% | 0.04% | -64.8% |
| Q3 2022 | $40,810,000 | +73.7% | 875,743 | +63.4% | 0.12% | +64.5% |
| Q2 2022 | $23,497,000 | -36.2% | 536,092 | +5.3% | 0.08% | -34.5% |
| Q1 2022 | $36,808,000 | +11.3% | 508,895 | +24.7% | 0.12% | +2.7% |
| Q4 2021 | $33,075,000 | +10.9% | 407,977 | +59.2% | 0.11% | -8.9% |
| Q3 2021 | $29,826,000 | +20.8% | 256,277 | +44.8% | 0.12% | +1.6% |
| Q1 2021 | $24,690,000 | -31.2% | 176,987 | -14.6% | 0.12% | -38.7% |
| Q4 2020 | $35,880,000 | +87.0% | 207,280 | +50.5% | 0.20% | +41.1% |
| Q3 2020 | $19,187,000 | -41.2% | 137,740 | -49.6% | 0.14% | -50.2% |
| Q2 2020 | $32,628,000 | +161.5% | 273,105 | +118.9% | 0.28% | +91.2% |
| Q1 2020 | $12,476,000 | -67.5% | 124,781 | -61.8% | 0.15% | -35.1% |
| Q4 2019 | $38,353,000 | +2557.9% | 326,301 | +1844.0% | 0.23% | +2180.0% |
| Q3 2019 | $1,443,000 | -56.6% | 16,785 | -67.3% | 0.01% | -52.4% |
| Q2 2019 | $3,323,000 | +378.8% | 51,255 | +362.0% | 0.02% | +320.0% |
| Q1 2019 | $694,000 | -89.2% | 11,095 | -93.3% | 0.01% | -89.1% |
| Q4 2018 | $6,410,000 | +137.7% | 164,826 | +248.4% | 0.05% | +283.3% |
| Q3 2018 | $2,697,000 | +873.6% | 47,310 | +1262.2% | 0.01% | +1100.0% |
| Q2 2018 | $277,000 | -41.2% | 3,473 | -36.1% | 0.00% | -50.0% |
| Q1 2018 | $471,000 | -94.5% | 5,432 | -94.2% | 0.00% | -94.1% |
| Q3 2017 | $8,583,000 | +15.3% | 94,444 | -5.6% | 0.03% | +9.7% |
| Q2 2017 | $7,443,000 | +118.2% | 100,000 | +174.7% | 0.03% | +93.8% |
| Q1 2017 | $3,411,000 | -72.2% | 36,400 | -78.5% | 0.02% | -75.8% |
| Q4 2016 | $12,275,000 | +291.9% | 168,931 | +463.1% | 0.07% | +266.7% |
| Q3 2016 | $3,132,000 | -43.4% | 30,000 | -60.0% | 0.02% | -50.0% |
| Q2 2016 | $5,532,000 | – | 75,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |